MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

17/12/2018
MorphoSys AG: Corporate Calendar 2019
12/12/2018
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-...
02/12/2018
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus...
26/11/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the...
19/11/2018
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA)...
15/11/2018
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys...
05/11/2018
MorphoSys AG Announces Third Quarter 2018 Results
01/11/2018
MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in...
29/10/2018
MorphoSys to Host Q3 2018 Conference Call on November 6, 2018
21/10/2018
MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165...

 

 

 

 

Interview with
Simon Moroney, CEO